Expert Highlights Safety Profile of Oral Azacitidine in Lower-Risk MDS
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Exploring The Use of Enfortumab Vedotin in Rare Genitourinary Cancers
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Asciminib May Be an “Attractive” Option in Newly Diagnosed CML Populations
Ongoing genomic profiling analyses in the ASC4FIRST trial may further determine which patients with CML may benefit from treatment with asciminib.
Expert Highlights Potential Utility of Amivantamab in Advanced EGFR+ NSCLC
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
Artificial Intelligence Tool May Improve Oncology Multi-Trial Matching
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Optimal Treatment Sequencing in Relapsed/Refractory Multiple Myeloma
Surbhi Sidana, MD, provides clinical insights on treatment sequencing strategies for patients with relapsed/refractory multiple myeloma.
Insights from CARTITUDE-4 and KarMMa-3 in R/R MM
Experts on multiple myeloma provide their impressions of the CARTITUDE-4 and KarMMa-3 studies, which led to the approval of cilta-cel and ide-cel in earlier lines of treatment for patients with relapsed/refractory disease.
CAR T-Cell Therapy in R/R MM: Treatment Selection, Safety, and Future Perspectives
Myeloma specialists have a comprehensive discussion on CAR T-cell therapy, highlighting treatment selection considerations, adverse event management strategies, unmet needs, and ongoing research.
Research on CAR T-Cell Therapy in Multiple Myeloma
Myeloma specialists discuss clinical trials investigating CAR T-cell therapies in patients with relapsed/refractory disease.
Efficacy Outcomes: Progression-Free Survival, Response Rates, and Duration of Response in MARIPOSA-2
This segment focuses on the key efficacy data on progression-free survival, response rates, and duration of response from MARIPOSA-2.
Patient Demographics and Baseline Disease Characteristics in MARIPOSA-2
In this segment the panelist reviews the baseline patient and disease characteristics across the three treatment arms in MARIPOSA-2.
Achieving Precision With Radiation Oncology Advancements in NSCLC
The use of CT scans may help practices adaptively plan and adjust radiotherapy courses for patients with non–small cell lung cancer.
Minimizing Toxicity in NSCLC Management With Proton Beam Radiotherapy
Patients with NSCLC who have comorbidities or frailty may also be able to receive treatment with fewer toxicities via proton beam radiotherapy.
Combining Immunotherapy With Radiation Oncology in NSCLC
Terrence T. Sio, MD, MS, emphasizes multidisciplinary collaboration for treating patients with NSCLC who may require more than 1 type of therapy.
Recent Bispecific Antibody Approvals in Relapsed/Refractory MM
The panel discusses recent updates on bispecific antibodies for patients with relapsed/refractory multiple myeloma, highlighting studies investigating talquetamab, teclistamab, and elranatamab.
Key Takeaways from the CARTITUDE-1 and KarMMa Studies
Focusing on later lines of therapy for patients with relapsed/refractory multiple myeloma, the panel provides key takeaways on the CARTITUDE-1 and KarMMa trials that investigated cilta-cel and ide-cel.
CAR T-Cell Therapy in Earlier Treatment Lines for Relapsed/Refractory Multiple Myeloma
A panel of experts on multiple myeloma introduce themselves and discuss recent CAR T-cell therapy approvals in earlier treatment lines for patients with relapsed/refractory disease.
How CAR T-Cell Therapy Impacts Relapsed/Refractory MM Treatment
Yi Lin, MD, PhD, provides insights on the impact of CAR T-cell therapy on the evolving multiple myeloma treatment landscape.
MARIPOSA-2 Phase 3 Study Design and Treatment Arms
This segment discusses the details of the phase 3 randomized MARIPOSA-2 trial design evaluating amivantamab plus chemotherapy vs amivantamab, lazertinib and chemotherapy vs chemotherapy alone in osimertinib-resistant EGFR-mutant NSCLC.
Background on Osimertinib Resistance Mechanisms and Unmet Needs Driving Evaluation of Novel Therapies
This segment introduces a discussion on the MARIPOSA-2 trial evaluating amivantamab plus chemotherapy or amivantamab, lazertinib and chemotherapy in EGFR-mutant NSCLC after osimertinib progression.
